Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 4

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis

Authors Vincenzo Savica, Domenico Santoro, Paolo Monardo, Agostino Mallamace, Guido Bellinghieri

Published 8 August 2008 Volume 2008:4(4) Pages 821—826

DOI http://dx.doi.org/10.2147/TCRM.S3075

Review by Single-blind

Peer reviewer comments 3

Vincenzo Savica1,2, Domenico Santoro1, Paolo Monardo2, Agostino Mallamace1, Guido Bellinghieri1

1Experimental and Clinic Department of Internal Medicine and Pharmacology, University of Messina, Italy; 2Nephrology and Dialysis Unit, Papardo Hospital, Messina, Italy

Abstract: Sevelamer carbonate is an anion exchange pharmaceutical, developed to improve on the performance of the non-absorbable, non-calcium, and metal-free phosphate binder sevelamer hydrochloride. Sevelamer carbonate is expected not to worsen metabolic acidosis, as previously reported during long-term treatment with sevelamer hydrochloride in hemodialysis (HD) patients. Carbonate is the alternate counterion to chloride on the sevelamer polymeric backbone, but the active poly(allylamine) responsible for phosphate (PO4) binding remains unaltered. Therefore, sevelamer carbonate is expected to reduce elevated serum phosphorus level, similarly to sevelamer hydrochloride. Sevelamers are prescribed in uremic HD patients to control hyperphosphatemia, but the carbonate has also been proposed for the treatment of chronic kidney disease (CKD) non-dialysis patients. Although hyperphosphatemia is regarded as a main contributor to increased mortality in the HD population because of cardiovascular calcification, metabolic acidosis has also been advocated as a major player in the increased mortality in this population, by engendering malnutrition, negative nitrogen balance, and inflammation. This paper reviews the evidence showing that sevelamer carbonate is as good as sevelamer hydrochloride in terms of hyperphosphatemia control in CKD, but with a better outcome in serum bicarbonate balance.

Keywords: chronic kidney disease, sevelamer carbonate, hyperphosphatemia, hemodialysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

In vivo and in vitro investigations of a nanostructured coating material – a preclinical study

Adam M, Ganz C, Xu W, Sarajian HR, Götz W, Gerber T

International Journal of Nanomedicine 2014, 9:975-984

Published Date: 14 February 2014

Quality of life measurement and outcome in aphasia

Spaccavento S, Craca A, Del Prete M, Falcone R, Colucci A, Di Palma A, Loverre A

Neuropsychiatric Disease and Treatment 2014, 10:27-37

Published Date: 17 December 2013

Do calcifying nanoparticles really contain 16S rDNA?

Shiekh FA

International Journal of Nanomedicine 2012, 7:5051-5052

Published Date: 18 September 2012

The neuro-ophthalmology of HIV-AIDS review of Neurobehavioral HIV Medicine

Sudhakar P, Kedar S, Berger JR

Neurobehavioral HIV Medicine 2012, 4:99-111

Published Date: 18 September 2012

Erratum

Xiao N, Shi S, Zhuang H

Hepatic Medicine: Evidence and Research 2011, 3:19-20

Published Date: 18 March 2011

Drug discovery and development for neglected diseases: the DNDi model

Eric Chatelain, Jean-Robert Ioset

Drug Design, Development and Therapy 2011, 5:175-181

Published Date: 16 March 2011

Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate

L Bellamy, N Rosencher, BI Eriksson

Patient Preference and Adherence 2009, 3:173-177

Published Date: 1 July 2009

Novel targets for immunotherapy in glomerulonephritis

Mary H Foster

Biologics: Targets and Therapy 2008, 2:531-545

Published Date: 12 September 2008

Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance

Jennifer S Carew, Steffan T Nawrocki, Francis J Giles, John L Cleveland

Biologics: Targets and Therapy 2008, 2:201-204

Published Date: 6 June 2008

Chitosan nanoparticles for oral drug and gene delivery

Katherine Bowman, Kam W Leong

International Journal of Nanomedicine 2006, 1:117-128

Published Date: 15 June 2006